Le Heuzey Jean-Yves, Marijon Eloi, Chachoua Karim, Waintraub Xavier, Lepillier Antoine, Otmani Akli, Lavergne Thomas, Pornin Maurice
Service de cardiologie A et rythmologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
Arch Cardiovasc Dis. 2008 Nov-Dec;101(11-12):787-91. doi: 10.1016/j.acvd.2008.09.015. Epub 2008 Nov 20.
Atrial fibrillation is, to date, a major problem of public health with an important cost in the health care system.
The therapeutic strategies for atrial fibrillation are complex and their outcomes have been disappointing globally. New ablative techniques have brought important advances but the patient's profile has to be taken into account in the choice of the therapeutic strategies. The renin-angiotensin system plays a major role in the phenomena of remodelling following the onset of atrial fibrillation.
Drugs blocking the renin-angiotensin system can have a real place in the treatment of atrial fibrillation, not only to maintain sinus rhythm but primarily to prevent cardiovascular accidents in these patients with atrial fibrillation and in some cases to prevent the occurrence of atrial fibrillation, for example in hypertensive patients.
迄今为止，心房颤动是一个重大的公共卫生问题，在医疗保健系统中耗费巨大。
心房颤动的治疗策略复杂，其全球治疗效果一直令人失望。新的消融技术取得了重要进展，但在选择治疗策略时必须考虑患者的情况。肾素 - 血管紧张素系统在心房颤动发作后的重塑现象中起主要作用。
阻断肾素 - 血管紧张素系统的药物在心房颤动治疗中可发挥实际作用，不仅用于维持窦性心律，主要是预防这些心房颤动患者发生心血管意外，在某些情况下还可预防心房颤动的发生，例如在高血压患者中。
